Drug
Pamiparib
Pamiparib: highest development phase Phase 3, developed by BeiGene, Hutchmed. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BeiGene, Hutchmed
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pamiparib capsule NCT03519230 | Phase 3 | Ovarian Cancer |
| Pamiparib NCT04603365 | Phase 2 | Clear Cell Papillary Renal Neoplasm |
| Pamiparib NCT03712930 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| Pamiparib NCT05494580 | Phase 1/2 | Ovarian Cancer |
Latest
No recent events.
Follow Pamiparib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.